UBS Group’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History
Bought
Maintained
Sold
UBS Group's AST.WS Position: Q3 2017 in Review
UBS Group sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 3,870 shares — an estimated $2K sold.
UBS Group first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $2K in Q2 2017. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.
- UBS Group reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
- UBS Group sold 3,870 Asterias Biotherapeutics Warrants shares in Q3 2017, an estimated $2K.
- UBS Group first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
- UBS Group's Asterias Biotherapeutics Warrants position peaked at $2K in Q2 2017.
- 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.
Based on UBS Group's 13F filing for Q3 2017, filed 14 Nov 2017.